Skip to Main Content

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.

The CDC recommends eligible people receive an updated COVID-19 booster designed for recent Omicron variants. Check eligibility and schedule an appointment on the CDC site today.

  • Indication
  • Important Safety Information
  • Full Prescribing Information
  • Medication Guide
  • Healthcare Professionals
  • En Español
    • INFORMACIÓN COMPLETA DE PRESCRIPCIÓN
    • FOLLETO PARA PACIENTES

CIBINQO (abrocitinib) is a prescription medicine to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

Close
home navigation icon
CIBINQO™ (abrocitinib) logo
home navigation icon
  • ABOUT
    CIBINQO
    • HOW CIBINQO WORKS
    • STUDY RESULTS
    • STUDY RESULTS IN TEENS
      (12-17 YEARS)
    • BEFORE & AFTER
    • HOW TO TAKE CIBINQO
  • SAFETY /
    SIDE EFFECTS
  • TALK TO
    YOUR DOCTOR
    • DOCTOR DISCUSSION TIPS
    • FIND A DOCTOR
  • SAVINGS &
    SUPPORT
    • OVERVIEW
    • SIGN UP FOR
      COPAY CARD
    • ACTIVATE COPAY CARD
    • SIGN UP FOR
      CIBINQO INFO
  • SHARE YOUR
    EXPERIENCE
  • ABOUT
    ECZEMA
  • HEALTHCARE PROFESSIONALS
  • En Español
    • Información Completa de
      Prescripción
    • Folleto para Pacientes

Please rotate your device to continue viewing this site.

Share your story & photos 

Made the move with CIBINQO? We’d love to hear about your or your teen’s experience

Has CIBINQO helped you get in front of eczema? Upload stories and/or photos to show us and the eczema community how. (Find tips for taking great photos here.)

Sharing experiences helps people understand what others have gone through and shows they're not alone in managing eczema.

If selected, stories and/or photos may be featured in CIBINQO materials. We will never share information publicly without your consent.

Some people have seen results with CIBINQO in 3 months. Check out clinical trial results here or see teen study results here.

First, tell us a little about yourself

Are you currently 18 years or older and a resident of the United States?

We are sorry, but you are not eligible to submit your experience. You must currently be 18 years or older and a resident of the United States.

Tell us more about yourself

I am:

Do you and/or your teen reside in California, Connecticut, Colorado, Virginia, or Utah?

We are sorry but you are not eligible to submit information about your teen's experience with CIBINQO due to state consumer privacy laws.

If selected, you or your teen may also be invited to participate in various public relations, marketing, and/or promotional activities on behalf of Pfizer. Please also note that patients who opt-in will be required to sign release authorization, including a HIPAA form, and provide consent for Pfizer to contact their physicians for additional background information, which may include medical records.

To understand how Pfizer may use your personal data, please read our Privacy Policy.

  • Step 1


    Info
  • Step 2


    Story
  • Step 3


    Photos
  • Step 4


    Review
Provide your information
Tell us your story
We'd love to hear about your experience in your own words. Need a suggestion?
  • How long have you or your teen been living with eczema?
  • What were symptoms like before treatment?
  • What are symptoms like now, during treatment with CIBINQO?
  • How has CIBINQO made a difference and why is that important?
0/1000 Characters
If selected, you or your teen may also be invited to participate in various public relations, marketing, and/or promotional activities on behalf of Pfizer. Please also note that patients who opt-in will be required to sign release authorization, including a HIPAA form, and provide consent for Pfizer to contact their physicians for additional background information, which may include medical records.
Next, would you like to share photos?
Upload photos that show the treatment journey, which could include:
  • Areas of eczema before treatment
  • The same area(s) while treating with CIBINQO (for example, after 2 weeks)
  • The same area(s) after treating with CIBINQO for 3 months
  • Life with eczema
If you’re not sharing photos today, please continue to next step
Instructions for uploading pictures:
  • Photos must be in a jpeg or png format
  • Do not use filters or alter photos in any way
  • File size must be 5 MB or smaller
See examples and tips for taking great photos
Upload your photos (optional)
If selected, you or your teen may also be invited to participate in various public relations, marketing, and/or promotional activities on behalf of Pfizer. Please also note that patients who opt-in will be required to sign release authorization, including a HIPAA form, and provide consent for Pfizer to contact their physicians for additional background information, which may include medical records.
Please review your information below, and when you're ready, use the Submit button to send it to us!
First Name:
John
Last Name:
Doe
Email:
[email protected]

Your story:

Photos:

If selected, you or your teen may also be invited to participate in various public relations, marketing, and/or promotional activities on behalf of Pfizer. Please also note that patients who opt-in will be required to sign release authorization, including a HIPAA form, and provide consent for Pfizer to contact their physicians for additional background information, which may include medical records.

To understand how Pfizer may use your personal data, please read our Privacy Policy.

Describe your photo

Your Before photo should capture the affected area
before taking CIBINQO
for the first time.
Date of photo
×
camera icon

How to take a great photo

Keep these tips in mind when taking photos to show how each affected area looked before and then during treatment with CIBINQO.

  • 1
    Good lighting is important to be able to clearly see your skin and recognize the body part being photographed.
  • 2
    Find a plain background so that there is nothing distracting in the photo.
  • 3
    Make sure the camera is in proper focus.
  • 4
    Be consistent. Use the same camera and create the same shot with the same angle, distance, lighting, and background for all of your photos.
  • 5
    Consider asking for help from a friend or family member.

Example

Before taking CIBINQO

With CIBINQO

taking CIBINQO™ (abrocitinib) comparison

Before taking CIBINQO

taking CIBINQO™ (abrocitinib) comparison

With CIBINQO

taking CIBINQO™ (abrocitinib) comparison

Not real patients. For illustrative purposes of before and after images only.
Individual results may vary. Not everyone will respond to treatment with CIBINQO.

IMPORTANT SAFETY INFORMATION and indication

CIBINQO may cause serious side effects, including:

Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have been hospitalized or died from these infections. Your risk of developing shingles may increase while taking CIBINQO.

Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.

Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:

  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired

CIBINQO can make you more likely to get infections or worsen infections you have. If you get a serious infection, your healthcare provider may stop treatment with CIBINQO until your infection is controlled.

There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).

Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.

There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.

Some people taking CIBINQO have had major cardiovascular events.

Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:

  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • weakness in one part or on one side of your body
  • slurred speech
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.

Stop taking CIBINQO and get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.

Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results.
Increased cholesterol levels. You may also have increases in the amount of fat found in your blood. Your doctor should check your cholesterol about 4 weeks after you start CIBINQO and then as needed.

During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.

Before taking CIBINQO, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have one that won't go away or keeps returning
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have had hepatitis B or hepatitis C
  • live, have lived, or traveled to certain areas (such as Ohio & Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or worsen when taking CIBINQO. Ask your healthcare provider if you're unsure if you have lived in an area where these infections are common
  • have had any type of cancer
  • have had blood clots in the veins of your legs or lungs
  • are a current or past smoker
  • have had a heart attack, other heart problems, or stroke
  • have kidney or liver problems
  • have abnormal blood tests (low platelet count or white blood cell count)
  • have high levels of fat in your blood (high cholesterol)
  • have any eye problems, including cataracts or retinal detachment
  • have recently received or are scheduled to receive any vaccinations. People who take CIBINQO should not receive live vaccines
  • are or plan to become pregnant. It is not known if CIBINQO will harm your unborn baby. Pfizer has a Pregnancy Exposure Registry for pregnant women who take CIBINQO to check your health and the health of your baby. If you are pregnant or become pregnant while taking CIBINQO, ask your healthcare provider how you can join this pregnancy registry, call 1-877-311-3770, or visit www.CIBINQOPregnancyRegistry.com to enroll
  • are breastfeeding or plan to breastfeed. It is not known if CIBINQO passes into your breast milk. You should not take CIBINQO while breastfeeding
  • are taking other medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. CIBINQO and other medicines may affect each other, causing side effects. Especially tell your healthcare provider if you take aspirin or any antiplatelet therapies. Ask your healthcare provider if you are unsure

The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.

Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.

CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of CIBINQO.

What is CIBINQO?

CIBINQO is a prescription medicine to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

It is not known if CIBINQO is safe and effective in children under 12 years of age.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.

Pfizer Dermatology Patient Access Logo

A personalized savings and support program

Learn more about financial assistance options and other resources by talking to a Patient Support Representative.

patient support representative

Call 1-833-956-DERM (1-833-956-3376)
Monday-Friday, 8:00 AM-8:00 PM ET

Eligibility required for financial assistance.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only).
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Eligibility required for financial assistance.

You are encouraged to report adverse events related to Pfizer products by calling
1-800-438-1985 (U.S. only).

If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

CIBINQO may cause serious side effects, including:

Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have been hospitalized or died from these infections. Your risk of developing shingles may increase while taking CIBINQO.

Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.

Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:

  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired

CIBINQO can make you more likely to get infections or worsen infections you have. If you get a serious infection, your healthcare provider may stop treatment with CIBINQO until your infection is controlled.

There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).

Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.

There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.

Some people taking CIBINQO have had major cardiovascular events.

Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:

  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • weakness in one part or on one side of your body
  • slurred speech
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.

Stop taking CIBINQO and get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.

Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results.
Increased cholesterol levels. You may also have increases in the amount of fat found in your blood. Your doctor should check your cholesterol about 4 weeks after you start CIBINQO and then as needed. 

During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.

Before taking CIBINQO, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have one that won't go away or keeps returning
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have had hepatitis B or hepatitis C
  • live, have lived, or traveled to certain areas (such as Ohio & Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or worsen when taking CIBINQO. Ask your healthcare provider if you're unsure if you have lived in an area where these infections are common
  • have had any type of cancer
  • have had blood clots in the veins of your legs or lungs
  • are a current or past smoker
  • have had a heart attack, other heart problems, or stroke
  • have kidney or liver problems
  • have abnormal blood tests (low platelet count or white blood cell count)
  • have high levels of fat in your blood (high cholesterol)
  • have any eye problems, including cataracts or retinal detachment
  • have recently received or are scheduled to receive any vaccinations. People who take CIBINQO should not receive live vaccines
  • are or plan to become pregnant. It is not known if CIBINQO will harm your unborn baby. Pfizer has a Pregnancy Exposure Registry for pregnant women who take CIBINQO to check your health and the health of your baby. If you are pregnant or become pregnant while taking CIBINQO, ask your healthcare provider how you can join this pregnancy registry, call 1-877-311-3770, or visit www.CIBINQOPregnancyRegistry.com to enroll
  • are breastfeeding or plan to breastfeed. It is not known if CIBINQO passes into your breast milk. You should not take CIBINQO while breastfeeding
  • are taking other medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. CIBINQO and other medicines may affect each other, causing side effects. Especially tell your healthcare provider if you take aspirin or any antiplatelet therapies. Ask your healthcare provider if you are unsure



The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.

Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.

CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of CIBINQO.

What is CIBINQO?

CIBINQO is a prescription medicine to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

It is not known if CIBINQO is safe and effective in children under 12 years of age.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.

Pfizer logo

Patients should always ask their doctors for medical advice
about adverse events.

This site is intended only for U.S. residents. The products
discussed in this site may have different product labeling in
different countries. The information provided is for
educational purposes only and is not intended to
replace discussions with a healthcare provider.

CIBINQO (abrocitinib) is available in 50 mg, 100 mg, and
200 mg pills.

Terms of Use Contact Us Sitemap Privacy Policy

© 2023 Pfizer Inc.
All rights reserved.
Pfizer, PO Box 29387, Mission, KS 66201
Last Updated: February 2023 PP-CIB-USA-0287

Terms of Use Contact Us Sitemap Privacy Policy

Patients should always ask their doctors for medical
advice about adverse events.

This site is intended only for U.S. residents. The
products discussed in this site may have different
product labeling in different countries. The
information provided is for educational purposes
only and is not intended to replace discussions
with a healthcare provider.

CIBINQO (abrocitinib) is available in 50 mg, 100 mg,
and 200 mg pills.

© 2023 Pfizer Inc.
All rights reserved.
Pfizer, PO Box 29387, Mission, KS 66201
Last Updated: February 2023 PP-CIB-USA-0287

© 2023 Pfizer Inc.
All rights reserved.
Pfizer, PO Box 29387, Mission, KS 66201
Last Updated: February 2023 PP-CIB-USA-0287

Pfizer logo

Pfizer logo​​​​​​​

Patients should always ask their doctors for medical advice about adverse events.

​​​​​​​This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for ​​​​​​​educational purposes only and is not intended to replace discussions with a healthcare provider.

CIBINQO (abrocitinib) is available in 50 mg, 100 mg, and 200 mg pills.

Terms of Use        Contact Us        Sitemap        ​​​​​​​Privacy Policy
© 2022 Pfizer Inc.All rights reserved.Pfizer, PO Box 29387,
Mission, KS 66201Last Updated: January 2022 PP-ABR-
​​​​​​​USA-0056
© 2022 Pfizer Inc.
All rights reserved.
Pfizer, PO Box 29387, Mission, KS 66201
Last Updated: January 2022 PP-ABR-USA-0056
  • Terms of Use
  • Contact Us
  • Sitemap
  • Privacy Policy
Patients should always ask their doctors for medical advice about adverse events.
This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
CIBINQO (abrocitinib) is available in 50 mg, 100 mg, and 200 mg pills.
© 2022 Pfizer Inc.
All rights reserved.
Pfizer, PO Box 29387, Mission, KS 66201
Last Updated: October 2022 PP-ABR-USA-0663
Pfizer logo